Phase 3Recruiting
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)
- Sponsor
- Hudson Biotech (Industry)
- Enrollment
- 2,539 planned
- Conditions
- Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
- Interventions
- Tirzepatide; Placebo; Reduced-calorie diet
- Ages
- adults, older adults
- Registry
- NCT07481747
Full record on ClinicalTrials.gov
From the registry
This Phase 3 study evaluates the efficacy and safety of once-weekly subcutaneous tirzepatide (a dual GIP and GLP-1 receptor agonist) at 5 mg, 10 mg, or 15 mg versus placebo, each used with a reduced-calorie diet and increased physical activity, in adults without type 2 diabetes who have obesity or are overweight with weight-related comorbidities. The primary efficacy assessment is at Week 72. Participants with prediabetes at randomization may continue in an additional long-term treatment period to assess progression to type 2 diabetes and longer-term weight outcomes.
Primary outcomes
- Mean percent change in body weight from randomization
- Percentage of participants achieving ≥5% body weight reduction from randomization
History
Study completion expected
Primary completion expected
Last registry update
Registered
Started
In the news
ResearchMedical Xpress (opens Medical Xpress in a new tab)
Resistance training cuts lean mass loss 25% during tirzepatide obesity treatment
In a 40-week randomized trial of 120 adults aged 50–70, three weekly sessions increased strength 10%, versus a 10% decline with tirzepatide alone, researchers report.
Also in Nature Medicine (opens Nature Medicine in a new tab)
